Article In English - Article in English

Sekilas Yayasan

Partners

Artikel Bebas

Tulisan Pribadi

Facebook Like

Article in English

Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant (Sarah Schillie, MD1; Aaron Harris, MD1; Ruth Link-Gelles, PhD1; José Romero, MD2; John Ward, MD1; Noele Nelson, MD1)

Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

Author : Sarah Schillie, MD¹; Aaron Harris, MD¹; Ruth Link-Gelles, PhD¹; José Romero, MD²; John Ward, MD¹; Noele Nelson, MD¹

Source : Morbidity and Mortality Weekly Report, April 20, 2018 / Vol. 67 / No. 15

Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, administered as a 2-dose series (0, 1 month) for use in persons aged ≥18 years. The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults. Seroprotective antibody to hepatitis B surface antigen (anti-HBs) levels were achieved in 90.0%–100.0% of subjects receiving HepB-CpG (Dynavax Technologies Corporation), compared with 70.5%–90.2% of subjects receiving Engerix-B (GlaxoSmithKline Biologicals). The benefits of protection with 2 doses administered over 1 month make HepB-CpG an important option for prevention of HBV.

Hepatitis B Update (reflection)

ReFlections Vol 44, May 4, 2018. RGA (Reinsurance Group of America, Incorporated^®)

Author : Akhilesh Pandey Senior Underwriter, Research and Manual Development. RGA India.

Abstract :

Hepatitis B is one of the world’s most prevalent infectious diseases today. The disease has been recognized for millennia, but the first actual breakthrough in understanding its etiology came more than 50 years ago, when it was discovered that the serum protein Australia Antigen (first discovered in Australian Aborigines) was in fact the surface antigen (HBsAg) of the hepatitis B virus (HBV). This discovery enabled the development of a successful hepatitis B vaccine in 1981.¹

Key facts

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
The virus is transmitted through contact with the blood or other body fluids of an infected person.
An estimated 257 million people are living with hepatitis B virus infection (defined as hepatitis B surface antigen positive).
In 2015, hepatitis B resulted in 887 000 deaths, mostly from complications (including cirrhosis and hepatocellular carcinoma).
Hepatitis B is an important occupational hazard for health workers.
However, it can be prevented by currently available safe and effective vaccine.